| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 5.0 | 3.0 | 4.0 |
| Total income | 200.0 | 220.0 | 170.0 |
| Exceptional items | 6.2 | 0.0 | 0.0 |
| Net profit | 28.1 | 47.8 | 18.9 |
| Operating margin | 17.7% | 28.5% | 16.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +48.70% |
|---|---|
| Net profit, quarter on quarter | -41.20% |
BSE results filing, NSE: THYROCARE. Figures extracted from the filing.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹536.85
- Market cap
- ₹8,545 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 48.5×Sector 56.3×
- Promoter holding
- 60.92%+0.00% QoQ
- FII holding
- 5.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Thyrocare Technologies Acquisition
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
Thyrocare Technologies Promoter Buying (Off-Market)
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
- Promoter stake change
- +51.02%
Thyrocare Technologies Merger & Restructuring
NCLT sanctioned the merger of Docon Technologies into API Holdings. Accordingly, the promoter's 51.02% stake in Thyrocare transfers to API Holdings, leaving the aggregate shareholding unchanged.